$1.63
0.62% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US6409791000
Symbol
NMRA

Neumora Therapeutics Stock price

$1.63
-0.72 30.64% 1M
-0.03 1.81% 6M
-8.97 84.62% YTD
-10.08 86.08% 1Y
-15.37 90.41% 3Y
-15.37 90.41% 5Y
-15.37 90.41% 10Y
-15.37 90.41% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
+0.01 0.62%
ISIN
US6409791000
Symbol
NMRA
Industry

Key metrics

Basic
Market capitalization
$262.4m
Enterprise Value
$64.2m
Net debt
positive
Cash
$217.6m
Shares outstanding
161.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
90.6%
Return on Equity
-84.9%
ROCE
-130.5%
ROIC
-4,813.4%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-264.1m | $-246.8m
EBIT
$-264.5m | $-256.9m
Net Income
$-252.1m | $-233.6m
Free Cash Flow
$-195.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
10.2% | 6.1%
EBIT
10.3% | 2.5%
Net Income
8.1% | 4.2%
Free Cash Flow
4.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.2
Short interest
12.2%
Employees
96
Rev per Employee
$0.0
Show more

Is Neumora Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Neumora Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Neumora Therapeutics forecast:

8x Buy
57%
6x Hold
43%

Analyst Opinions

14 Analysts have issued a Neumora Therapeutics forecast:

Buy
57%
Hold
43%

Financial data from Neumora Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 67 67
20% 20%
-
- Research and Development Expense 197 197
13% 13%
-
-264 -264
10% 10%
-
- Depreciation and Amortization 0.49 0.49
26% 26%
-
EBIT (Operating Income) EBIT -265 -265
10% 10%
-
Net Profit -252 -252
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Neumora Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neumora Therapeutics Stock News

Neutral
Seeking Alpha
19 days ago
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development officer - Corporate Participant Helen Rubinstein - Head of Investor Relations Joshua Pinto - President Michael Lee Milligan - CFO & Principal Accounting Officer Nicholas Brandon - Chief Scientific Off...
Positive
The Motley Fool
19 days ago
Neumora Therapeutics (NMRA -4.22%), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most significant news was a reduction in both research and development spending and overall net loss, while the company advanced multiple programs in its clinical pipeline.
Neutral
GlobeNewsWire
19 days ago
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity (DIO) mouse model expected in 2025 Entering catalyst-rich period wit...
More Neumora Therapeutics News

Company Profile

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Head office United States
CEO Paul Berns
Employees 96
Founded 2019
Website neumoratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today